Latest lung cancer Stories

The Lung Cancer Asbestos Victims Center says, "We now believe the worst kept secret for the vast majority of lung cancer victims in the United States is if they were exposed to asbestos in their workplace they may be eligible for significant financial compensation, and we want to hear from these victims, or their family members so we can try to get them on a path towards financial compensation, and at the same time we want to make certain all victims of mesothelioma have the best...

The Lung Cancer Asbestos Victims Center is now urging all diagnosed victims of mesothelioma, or victims of any type of lung cancer, who were exposed to asbestos at work to call them about possible significant financial compensation, and the names, and specific contacts for the leading mesothelioma, or asbestos exposure law firms in the nation, because the best mesothelioma law firms, get the best possible financial compensation results for the people they represent, when it comes to...

Data Presented at American Society of Clinical Oncology (ASCO) on two Boehringer Ingelheim Phase III Oncology Compounds, Afatinib* and Nintedanib*, Show Progression Free Survival in Patients with Advanced Non-Small Cell Lung Cancer BURLINGTON, ON, May 16, 2013 /CNW/ - New research taking place right here on Canadian soil is shedding light on the nation's number one cancer killer,(i) lung cancer.  Boehringer Ingelheim (Canada) Ltd. today announced data from Phase III clinical...

The Lung Cancer Asbestos Victims Center is aggressively attempting to make certain every diagnosed victim of mesothelioma, or victim of lung cancer who had long term exposure to asbestos in the workplace calls them at 866-714-6466 for the names, and contacts for the best possible mesothelioma lawyers, or asbestos compensation law firms, because the most skilled mesothelioma lawyers, and or asbestos exposure law firms really do get better financial compensation results for their...

The 4th Annual BioConference Live Clinical Diagnostics Virtual Conference presents cutting-edge research in clinical diagnostics May 29-31, 2013. Yorba Linda, CA (PRWEB) May 15, 2013 BioConference Live is a premiere producer of online conferences aimed at covering a variety of science verticals, including Clinical Diagnostics, Genetics & Genomics, Cancer Research & Discovery, and Laboratory Animal Science. Each annual conference is entirely online for easy attendance and free for...

Los Angeles Cancer Institute team member shares her personal journey of overcoming skin cancer. Los Angeles, CA (PRWEB) May 15, 2013 When 60-year-old Edna Mayorga first accepted a job with the large cancer care provider, Los Angeles Cancer Institute, a division of 21st Century Oncology of California, she did not know she would eventually become a patient. In November 2012, the 16-year veteran Patient Care Coordinator was diagnosed with basal cell carcinoma – skin cancer on her nose....

For U.S. Media Only RIDGEFIELD, Conn., May 15, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced data from two Phase III clinical trials involving two different investigational oncology compounds - afatinib* and nintedanib* - in two distinct patient populations with advanced non-small cell lung cancer (NSCLC). Results from both studies will be presented at the 49(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) in...

For U.S. Media Only RIDGEFIELD, Conn., May 15, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced the upcoming presentation of data from 14 abstracts involving three of the company's investigational oncology compounds - afatinib*, nintedanib* and volasertib*. Results - to be presented at the 49(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2013 - are from Boehringer Ingelheim's robust...

Treatment for NSCLC Refractory to Other Therapy AUSTIN, Texas, May 15, 2013 /PRNewswire/ -- XBiotech, a privately held biotechnology company, announced today its recent findings for Non-Small Cell Lung Cancer (NSCLC). Sixteen advanced NSCLC patients were treated at MD Anderson Cancer Center with the Company's True Human Therapeutic Antibody XILONIX(TM). The patients receiving XILONIX had failed all conventional therapy and had progressive disease upon receiving treatment with...

The primary goal of the Lung Cancer Asbestos Victims Center is helping all US Navy Veterans, who have been diagnosed with mesothelioma, or any type of lung cancer, and they are asking one simple question, "Where were you exposed to asbestos on your ship, because where you were exposed can make a huge difference when it comes to financial compensation, especially for US Navy Veterans, who are victims of mesothelioma?" If a US Navy Veteran has been diagnosed with mesothelioma, the...